Skandinaviska Enskilda Banken (SEB)
SCMP

Skandinaviska Enskilda Banken (SEB)’s Sucampo Pharmaceuticals, Inc. SCMP Stock Holding History

Skandinaviska Enskilda Banken (SEB)’s Portfolio SCMP Stock Details SCMP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-188,700
Closed -$3.39M – 737
2017
Q4 		$3.39M Sell
188,700
-83,400
-31% -$1.03M 0.03% 345
2017
Q3 		$3.21M Hold
272,100
– – 0.03% 367
2017
Q2 		$2.86M Sell
272,100
-18,900
-6% -$193K 0.03% 394
2017
Q1 		$3.2M Buy
291,000
+16,900
+6% +$196K 0.03% 359
2016
Q4 		$3.71M Sell
274,100
-121,300
-31% -$1.69M 0.04% 279
2016
Q3 		$4.87M Buy
395,400
+27,500
+7% +$324K 0.05% 265
2016
Q2 		$4.04M Buy
367,900
+255,500
+227% +$2.86M 0.05% 288
2016
Q1 		$1.23M Hold
112,400
– – 0.01% 551
2015
Q4 		$1.99M Buy
+112,400
New +$2.02M 0.03% 385

Other funds holding SCMP

GT
Glenmede Trust Philadelphia, Pennsylvania $20.4B AUM
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
AIM
Advantage Investment Management Cedar Rapids, Iowa $128M AUM 3.61% 1-Year Est. Return

Skandinaviska Enskilda Banken (SEB)'s SCMP Position: Q1 2018 in Review

Skandinaviska Enskilda Banken (SEB) sold out of Sucampo Pharmaceuticals, Inc. (SCMP) in Q1 2018, closing a stake of 188,700 shares — an estimated $3.39M sold.

Skandinaviska Enskilda Banken (SEB) first reported a position in SCMP in Q4 2015 and held it in 9 quarters. The position peaked at $4.87M in Q3 2016. 3 funds tracked by Wall St. Rank hold SCMP as of Q1 2018.

  • Skandinaviska Enskilda Banken (SEB) reported no remaining Sucampo Pharmaceuticals, Inc. position as of Q1 2018 after selling out during the quarter.
  • Skandinaviska Enskilda Banken (SEB) sold 188,700 Sucampo Pharmaceuticals, Inc. shares in Q1 2018, an estimated $3.39M.
  • Skandinaviska Enskilda Banken (SEB) first reported a position in Sucampo Pharmaceuticals, Inc. in Q4 2015 and held it in 9 quarters.
  • Skandinaviska Enskilda Banken (SEB)'s Sucampo Pharmaceuticals, Inc. position peaked at $4.87M in Q3 2016.
  • 3 funds tracked by Wall St. Rank held Sucampo Pharmaceuticals, Inc. as of Q1 2018.

Based on Skandinaviska Enskilda Banken (SEB)'s 13F filing for Q1 2018, filed 30 Apr 2018.